Detalhe da pesquisa
1.
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
J Neurooncol
; 152(2): 233-243, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33517558
2.
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.
Pharmacology
; 100(5-6): 229-242, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743107
3.
Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Bioorg Med Chem Lett
; 22(24): 7615-22, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23103095
4.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Nature
; 435(7042): 677-81, 2005 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-15902208
5.
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Mol Cancer Ther
; 19(10): 2117-2125, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32847977
6.
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor.
ACS Med Chem Lett
; 11(10): 1829-1836, 2020 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33062160
7.
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.
Clin Cancer Res
; 14(11): 3268-77, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519752
8.
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.
Mol Cancer Ther
; 7(10): 3265-74, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18852130
9.
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Mol Cancer Ther
; 17(4): 795-805, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483208
10.
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
J Med Chem
; 50(4): 641-62, 2007 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17256834
11.
The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors.
Neoplasia
; 19(9): 695-706, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28787674
12.
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
Mol Cancer Ther
; 16(8): 1511-1520, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468776
13.
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Mol Cancer Ther
; 4(6): 977-86, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15956255
14.
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Mol Cancer Ther
; 15(5): 1132-44, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26939706
15.
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
Mol Cancer Ther
; 15(4): 661-9, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26846818
16.
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Sci Transl Med
; 7(279): 279ra40, 2015 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25787766
17.
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.
ACS Med Chem Lett
; 5(10): 1088-93, 2014 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25313317
18.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med
; 19(2): 202-8, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23291630
19.
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Mol Cancer Ther
; 10(12): 2340-9, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21914853
20.
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
Cancer Chemother Pharmacol
; 66(5): 869-80, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20099064